These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 1554914)
1. Choosing a treatment modality for ESRD. The Canadian perspective. Prichard S ASAIO J; 1992; 38(1):1-2. PubMed ID: 1554914 [No Abstract] [Full Text] [Related]
2. Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore. Yang F; Lau T; Luo N Nephrology (Carlton); 2016 Aug; 21(8):669-77. PubMed ID: 26566750 [TBL] [Abstract][Full Text] [Related]
3. Cost analysis of alternative treatments in end-stage renal disease. Karlberg I Transplant Proc; 1992 Feb; 24(1):335. PubMed ID: 1539301 [No Abstract] [Full Text] [Related]
11. Is CAPD a viable option among ADPKD with end stage renal disease population in India? Its outcomes and economics. Kaul A; Dharshan R; Bhadhuaria D; Prasad N; Gupta A; Sharma RK Saudi J Kidney Dis Transpl; 2015 Sep; 26(5):906-11. PubMed ID: 26354561 [TBL] [Abstract][Full Text] [Related]
12. What is the evidence that peritoneal dialysis is underutilized as an ESRD therapy? Gokal R; Blake PG; Passlick-Deetjen J; Schaub TP; Prichard S; Burkart JM Semin Dial; 2002; 15(3):149-61. PubMed ID: 12100453 [No Abstract] [Full Text] [Related]
13. Costs and added value of haemodialysis and peritoneal dialysis outsourcing agreements. Lamas Barreiro JM; Alonso Suárez M; Saavedra Alonso JA; Gándara Martínez A Nefrologia; 2011; 31(6):656-63. PubMed ID: 22130280 [TBL] [Abstract][Full Text] [Related]
15. The economic cost of dialysis: a comparison between peritoneal dialysis and in-center hemodialysis in a Spanish unit. Rodríguez-Carmona A; Perez Fontán M; Bouza P; García Falcón T; Valdés F Adv Perit Dial; 1996; 12():93-6. PubMed ID: 8865880 [TBL] [Abstract][Full Text] [Related]
16. The costs of dialysis in Canada. Prichard SS Nephrol Dial Transplant; 1997; 12 Suppl 1():22-4. PubMed ID: 9075224 [TBL] [Abstract][Full Text] [Related]
17. Non-medical factors that impact on ESRD modality selection. Nissenson AR; Prichard SS; Cheng IK; Gokal R; Kubota M; Maiorca R; Riella MC; Rottembourg J; Stewart JH Kidney Int Suppl; 1993 Feb; 40():S120-7. PubMed ID: 8445833 [No Abstract] [Full Text] [Related]
18. Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies. De Vecchi AF; Dratwa M; Wiedemann ME Nephrol Dial Transplant; 1999; 14 Suppl 6():31-41. PubMed ID: 10528710 [TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Hooi LS; Lim TO; Goh A; Wong HS; Tan CC; Ahmad G; Morad Z Nephrology (Carlton); 2005 Feb; 10(1):25-32. PubMed ID: 15705178 [TBL] [Abstract][Full Text] [Related]
20. The dilemmas of patient treatment for end-stage renal disease. Schmidt RW; Blumenkrantz M; Wiegmann TB Am J Kidney Dis; 1983 Jul; 3(1):37-47. PubMed ID: 6346866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]